Experimental pancreatic cancer vaccine shows promise

Half of patients who received an experimental pancreatic cancer vaccine developed by Roche and BioNTech in an early-stage trial were still alive, most with no signs of disease recurrence, more than three years after treatment, according to a report published by Reuters.

Informatie preluata din publicatia "Bursa" - citeste integral articolul - click aici